NCT05255133View on ClinicalTrials.gov

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

June 23, 2022

Study Completion Date

June 23, 2022

Conditions
Neuroendocrine Tumors
Interventions
OTHER

Liquid biopsies

Blood sampling will be done at regular intervals

OTHER

Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)

Scans will be done at regular intervals

Trial Locations (8)

2100

AZ Monica, Deurne

2170

ZNA, Merksem

2390

AZ Voorkempen, Malle

2610

GZA, Antwerp

2650

Antwerp University Hospital, Edegem

2880

AZ Rivierenland, Bornem

2930

AZ Klina, Brasschaat

9100

AZ Nikolaas, Sint-Niklaas

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

University Hospital, Antwerp

OTHER

lead

Universiteit Antwerpen

OTHER

NCT05255133 - A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment | Biotech Hunter | Biotech Hunter